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SUMMARY AT A GLANCE
This study described a large cohort of
Australian general practice-based patients
identiﬁed as having chronic kidney disease
(CKD), utilizing data from MedicineInsight
dataset, and aimed to compare this
dataset against the Australian Bureau of
Statistics’ CKD prevalence estimates. The
results provided important and interesting
sociodemographic data of CKD in
Australia, and might further assist general
practitioners to optimize the prevention
and care of CKD patients.
ABSTRACT:
Aim: To describe sociodemographic characteristics and comorbidities of a
large cohort of Australian general practice-based patients identiﬁed as hav-
ing chronic kidney disease (CKD), using data from National Prescribing Ser-
vice (NPS) MedicineWise’s MedicineInsight dataset, and compare this
dataset to the 2011–2012 Australian Health Survey’s (AHS) CKD prevalence
estimates.
Methods: This was a cohort study using deidentiﬁed, longitudinal, elec-
tronic health record data collected from 329 practices and 1 483 416
patients distributed across Australia, from 1 June 2013 until 1 June 2016.
Two methods were used to calculate the CKD prevalence. One used the
same method as used by the 2011–2012 AHS, based on one estimate of the
estimated glomerular ﬁltration rate (eGFR) or albumin/creatinine ratios
(ACR). The other deﬁned CKD more rigorously using eGFR or ACR results
at least 90 days apart.
Results: In 2016, of 1 310 602 active patients, 710 674 (54.2%) did not have
an eGFR or ACR test, while 524 961 (40.1%) had an eGFR or ACR test but
did not meet AHS criteria for CKD. Age–sex adjusted rates of CKD (com-
pared to AHS) were CKD 1–0.45% (3.9%), CKD 2–0.62% (2.5%), CKD 3a:
3.1% (2.7%), CKD 3b: 1.14% (0.6%), CKD 4–5: 0.41% (0.3%). The CKD cohort
deﬁned more rigorously using eGFR and ACR measures >90 days apart, had
comorbidities of atrial ﬁbrillation (30.5%), cardiovascular disease (25.0%),
diabetes mellitus (17.1%) and hypertension (14.8%).
Conclusion: The MedicineInsight dataset contains valuable and timely infor-
mation about Australian patients with CKD, and provides prevalence esti-
mates similar to those from AHS data.
Chronic kidney disease (CKD) is a worldwide health problem
with an increasing incidence and prevalence, especially in devel-
oped countries, such as Australia.1 It is usually associated with
multimorbidity, even at moderate, stage 3 levels.2 The current
standard for estimating the prevalence of CKD in the Australian
population is the Australian Bureau of Statistics (ABS) dataset,
incorporating self-report surveys and based on a 2011–2012
sample of 31 937 Australians.3,4 Due to the reliance on health
literacy and recall, this approach may not produce the most
accurate picture of the health of Australians.5
In the United Kingdom, the Clinical Practice Research
Datalink (CPRD) national registry, comprising primary care
data from almost 3 million patient electronic health record
(EHR), has been shown to have good external validity for
estimating the prevalence of reduced kidney function (glo-
merular ﬁltration rate, GFR <60 mL/min per 1.73 m2).6 In
contrast, large datasets from general practices in Australia
have not previously been used, although the country now
seems well suited to such an approach. While laboratories in
only 18% and 8% of countries report routine estimates of
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and proteinuria measures, respectively,7 to assist in the rec-
ognition of CKD, Australian general practitioner (GP) have
had access to routine GFR estimates for 10 years.8 On aver-
age, 85% of Australians visit their general practitioner at
least once in a year.9 The details of these visits will typically
be recorded electronically; by 2014 Australian GP were
using EHR 98% of the time for prescribing and 70%
reported a paperless ofﬁce.9 Paper-based GP recording of
consultation details, using relatively small patient popula-
tions, has been previously used to extrapolate the preva-
lence of chronic conditions and multi-morbidity.10 While
the collection of cross-sectional de-identiﬁed data from
Australian general practice EHR has been described, most
studies to date have also used relatively small populations or
been limited geographically.11
The National Prescribing Service (NPS) MedicineWise
MedicineInsight dataset is the largest and most representa-
tive general practice/primary care clinical dataset yet devel-
oped in Australia12,13; it currently has over 650 recruited
general practices, providing a database of over 3.6 million
records of Australian patients. Since 2013, general practices
and GP across Australia have been able to contribute their
data. The dataset includes information from codable and
free-text ﬁelds within an EHR, such as medication pre-
scribed and vaccines given, biometrics, investigations
ordered and conditions managed for each patient. Updating
the data every 2–4 weeks provides a longitudinal picture for
each person in the database13 .
This study aimed to describe a large cohort of Australian
general practice-based patients identiﬁed as having CKD,
utilizing data from NPS MedicineWise’s MedicineInsight
dataset, and to compare this dataset against the ABS’s CKD
prevalence estimates.4 The MedicineInsight dataset was also
used to describe associated sociodemographic characteristics
and comorbidities for Australians with CKD.
METHODS
The NPS MedicineWise’s MedicineInsight data has been
described elsewhere.12 This dataset was collected from
329 participating practices representing 1 483 416 active
patients from 1st June 2013 until 30th June 2016. Active
patients are deﬁned as those visiting the general practice at
least three times over the previous 2 years.14 We used two
methods to calculate the prevalence of CKD in our population.
In the ﬁrst method, data collected from 01 January 2013 to
01 June 2016 was used to identify patients ≥18 years of age
with probable CKD stages 1–5.15 All staging was based on esti-
mated glomerular ﬁltration rate (eGFR) and/or urinary
albumin-to-creatinine ratio (ACR) results, as per the ABS’s
CKD criteria.4 CKD stage 1 classiﬁcation depended on the
presence an eGFR ≥90 mL/min per 1.73 m2 and albuminuria
of ≥2.5 for males or ≥3.5 for females (urine ACR mg/mmol).
CKD stage 2 resulted from an eGFR of 60–89 mL/min per
1.73 m2 and the same ACR ﬁnding. CKD stage 3a
classiﬁcation depended on ﬁnding an eGFR of 45–59 mL/min
per 1.73 m2, with CKD stage 3b on ﬁnding an eGFR of
30–44 mL/min per 1.73 m2. CKD stages 4–5 depended on an
eGFR of <30 mL/min per 1.73 m2. We used each patient’s
ﬁrst eGFR and ﬁrst ACR in each calendar year to determine
their stage of CKD, as per the Australian Health Survey
(AHS).3 Patients were only included in the dataset by the 30th
of June in the nominated year if they had a general practice
encounter or a pathology result within the previous year.
In the second method, CKD status was determined by two
eGFR results <60 mL/min per 1.73 m2 at least 90 days
apart, and/or presence of albuminuria for >90 days of
≥3.5 mg/mmol for females, and ≥2.5 mg/mmol for males.
We have labelled this cohort as ‘Two eGFRs or ACRs CKD’.
This method matches that recommended for the diagnosis
of CKD in Australian general practice.16
Both CKD cohorts were determined using pre-calculated
eGFR measurement results routinely sent to general prac-
tices as part of a pathology dataset. The modiﬁcation of diet
in renal disease (MDRD) equation had been used to calcu-
late the eGFR in 85% of the pre-calculated eGFR results,
while the remainder were based on the chronic kidney dis-
ease epidemiology collaboration (CKD-Epi) equation. To
standardize the mix of MDRD and CKD-EPI calculations of
raw data eGFR, all eGFR were recalculated using the CKD-
EPI (2009) formula.17 As data had been obtained in 5 years
age groups from NPS MedicineWise MedicineInsight, the
patient’s age at the time of testing was calculated as the
median age of their respective 5 years group minus the
number of days prior to the end of the study period that the
test results were provided. ACR measurements were a
stand-alone pathology request.
The diagnoses of anxiety disorder, atrial ﬁbrillation (AF),
cardiovascular disease (CVD), CKD, diabetes mellitus (dia-
betes) and hypertension (HT) were recorded based on
‘condition ﬂags’ provided by NPS MedicineWise Medici-
neInsight. Condition ﬂags are devised using algorithms that
analyse coded and free-text information in the ﬁelds
of either ‘encounter_reason’, ‘prescription_reason’, or
‘diagnosis_reason’,18,19 .
Statistical analysis
All data cleaning, data manipulation and statistical analysis
were completed using the statistical and graphical comput-
ing language of R (https://www.R-project.org/). Pearson’s χ2
test of independence was used to determine differences in
proportions between the CKD cohort and all active patients
in the dataset.
Age–sex adjustment of raw prevalence rates, and their
95% conﬁdence intervals (CI), were completed using the
‘Age-standardization – direct method’ described by Boyle
and Martin.20 Potential clustering by practice was not
accounted for in the calculation of the 95% CI. The refer-
ence population for age–sex standardization was from the
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Australian Demographic Statistics (June 2016) report from
the Australian Bureau of Statistics.21
Rurality was based on Australian Bureau of Statistics’
(ABS) Australian Statistical Geography Standard (ASGS)
remoteness areas.22 Socio-economic index was also based
on patient postcode, using the socio-economic indexes for
area (SEIFA) of relative socio-economic advantage and dis-
advantage decile. SEIFA is ranked from 1 (most disadvan-
taged area) to 10 (most advantaged)23 .
RESULTS
The number of active patients varied over the three annual
periods from 1 041 529 to 1 310 602, reﬂecting the increas-
ing enrolment of general practices in the NPS MedicineWise
MedicineInsight program over that period. As noted in
Table 1, while the number of patients in the dataset grew
each year from 2014 to 2016 the percentage of patients not
tested with either a measure of eGFR or ACR, those who
were tested but did not meet AHS criteria for CKD, and
those who met criteria for CKD 1–5 remained relatively
stable.
Table 2 describes the unadjusted prevalence of CKD for
adult males and females, in 10 years age groupings in the
year from 02 June 2015 to 01 June 2016. This year was the
latest in the dataset. In Table 1, three annual time-periods
from June 2nd to June 1st each year (2014–2016) were
used to compare the age- and sex-adjusted prevalence for
each CKD stage with the ﬁgures obtained from the AHS in
2011–2012.3 Figure 1 demonstrates the selection process
leading to the more rigorous deﬁnition of CKD.16 Of
1 483 416 active patients, 524 430 (35%) did not have an
eGFR or ACR measurement in the study period. Of the
958 986 patients with at least one eGFR or ACR, 893 682
(93% of those tested) did not have an eGFR <60 mL/min
per 1.73 m2, or an abnormal ACR. Of the 113 517 with
results potentially classifying them as having CKD 3–5, only
61 102 (54%) had 2 measures at least 90 days apart on
which to base a more accurate diagnosis of CKD 3–5.
Table 3 presents MedicineInsight data collected in the
period 02 June 2015 until 01 June 2016 (denoted as 2016).
Socio-demographic characteristics, smoking status and
comorbidities of are presented as rows. As columns are: all
2016 MedicineInsight patients, described as current, who
had either a general practice encounter, or any pathology
result entered into their EHR during the time period; ‘Two
eGFRs and/or 2ACRs CKD’ cohort as a percentage of all
2016 patients; patients who have ever had an eGFR as a
percentage of all 2016 patients; patients who had an eGFR
of <60 mL/min per 1.73 m2 as a percentage of all 2016
patients; and patients who had an eGFR <60 mL/min per
1.73 m2 as a percentage of those who had an eGFR in 2016.
Each group with eGFR measures were then age- and sex-
adjusted against ABS data.
Figure 2 is a Venn diagram illustrating the mix of comor-
bidities in patients from the ‘Two eGFRs and/or 2 ACRs
CKD’ cohort.
DISCUSSION
The NPS MedicineWise MedicineInsight database provides a
new tool for measuring the prevalence of CKD in the
Australian population. Because the data is longitudinal with
multiple pathology results per patient, it is possible to be more
rigorous in deﬁning a cohort of patients with CKD based on
the requirement to more properly deﬁne CKD as having
Table 1 Comparison of yearly MedicineInsight data to Australian Health Study age and sex-adjusted results by the Australian Bureau of Statistics.
2014† 2015† 2016† Australian
Health
Study
Data
n (%) Age–sex adjusted %
(95% conﬁdence
intervals (CI))
n (%) Age–sex adjusted %
(95% CI)
n (%) Age–sex adjusted %
(95% CI)
Age–sex
adjusted
by ABS‡
No Indicators§ 394 961 (37.9%) 35.65% (34.62–36.69) 502 554 (38.5%) 37.18% (36.14–38.22) 524 961 (40.1%) 38.83% (37.77–39.88) 81.6%
Stage 1 3802 (0.4%) 0.35% (0.22–0.48) 5430 (0.4%) 0.41% (0.27–0.55) 5876 (0.4%) 0.45% (0.30–0.59) 3.9%
Stage 2 5708 (0.5%) 0.47% (0.33–0.61) 6982 (0.5%) 0.49% (0.35–0.64) 8145 (0.6%) 0.58% (0.42–0.74) 2.5%
Stage 3a 33 015 (3.2%) 2.57% (2.27–2.87) 37 362 (2.9%) 2.57% (2.25–2.88) 40 666 (3.1%) 2.79% (2.46–3.11) 2.7%
Stage 3b 10 938 (1.1%) 0.84% (0.67–1.02) 13 482 (1.0%) 0.92% (0.73–1.11) 14 941 (1.1) 1.02% (0.82–1.22) 0.6%
Stages 4–5 3297 (0.3%) 0.26% (0.16–0.36) 4555 (0.3%) 0.32% (0.20–0.43) 5339 (0.4%) 0.37% (0.24–0.49) 0.3%
Not tested¶ 589 808 (56.6%) 59.85% (58.81–60.89) 736 105 (56.3%) 58.11% (57.07–59.14) 710 674 (54.2%) 55.97% (54.93–57.02) 8.4%
Active during
this year††
1 041 529 – 1 306 470 – 1 310 602 – –
†Year is from June 2nd to June 1st the following year1. ‡Percentages are based on the Australian Health Study/Australian Bureau of Statistics deﬁnition of
chronic kidney disease . §Had an estimated glomerular ﬁltration rate and or albumin/creatinine ratios, but did not meet Australian Health Study/Australian
Bureau of Statistics deﬁnition for chronic kidney disease . ¶Did not have a recorded albumin/creatinine ratios or estimated glomerular ﬁltration rate in year.
††Patients were included in this analysis if they had a GP encounter or pathology measurement within that year.
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eGFR that remain at or below cut-off points over a period of
90 days or more.16 The resultant large cohort is then useful to
view as a more speciﬁc group with which to investigate fac-
tors leading to disease stability or progression. This could form
an important CKD research tool and offers the same beneﬁts
as a registry but across earlier stages of CKD.24
The age- and sex-adjusted prevalence rates with the Med-
icineInsight dataset compare favourably with AHS ﬁgures
for CKD stages 3a to 4–5, while ﬁgures for CKD 1–2 show a
lower prevalence compared to AHS data.3 This is likely to
reﬂect the reasons for ordering pathology tests in general
practice. Patients who may be diagnosable as CKD 1–2 may
be comparatively well, presenting less often to their GP and
having fewer reasons to have an eGFR and/or ACR ordered,
while those with, for example, cardiovascular disease and
diabetes are likely to have their renal function monitored
regularly as part of overall management.16
The MedicineInsight dataset showed a higher prevalence of
CKD in Aboriginal and Torres Strait Islander (ATSI) popula-
tions (5.51%) than non-ATSI populations (4.22%). There was
also a clear correlation between CKD prevalence and areas of
socio-economic disadvantage, with prevalence increasing from
3.54% in the most advantaged quintile to 4.63% in the most
disadvantaged quintile. These ﬁndings are consistent with pat-
terns of CKD prevalence reported in the AHS.1
The AHS dataset has limitations, noting that the current
sample is dated - have been collected in 2011–2012, and is
based on a relatively small sample, with the data based on
10 391 of 27 636 Australians over the age of 12 years sub-
mitting to one estimate of their eGFR, and 11 267 of
30 329 over the age of 5 years submitting a urine sample
for an ACR.3 Although the AHS results were then
weighted against population benchmarks chosen to reduce
random and systematic errors, the judicious use of the
NPS MedicineWise MedicineInsight dataset could form a
very useful adjunct noting the beneﬁts of being drawn
from a large, well-distributed population of Australians, its
timeliness and associated extra data such as comorbidity
prevalence.
The ﬁnding that 88% of patients in the ‘current’ cohort
had a GP encounter or pathology result during the period
02 June 2015 until 01 June 2016 (denoted as 2016) ﬁts well
with estimates that, on average, 85% of Australians visit
their GP annually.9 The higher percentage of patients with
ﬂagged conditions within the ‘current’ 2016 cohort reﬂects
the expected higher engagement rates of these patients with
their general practice. Hence, over a year 95.2% of patients
with AF, 92.1% with anxiety disorder, 94.9% with CVD,
94.7% with diabetes, 94.9% with HT and 97.1% with CKD
saw their GP or had recorded in their EHR a pathology
result.
Age- and sex-adjusted MedicineInsight data suggests
40–45% of Australian patients had an eGFR estimate in
2016. We do not know why these tests were undertaken
Table 2 Prevalence of patients in ‘two eGFRs and/or ACRs CKD’ cohort by gender and age-group
Age-group MedicineInsight Two eGFRs and/or
ACRs CKD cohort
Encounter
in 2016
Australian Health Study CKD Stages based on 2016 Encounter Data
Females n % n % of
medicine
Insight
Dataset
n Stage 3a n (%)# Stage 3b n (%)# Stage 4–5 n (%)† Totaln (%)†
20–29 150 334 17.73% 34 0.02% 127 038 27 (0.02%) 9 (0.01%) 11 (0.01%) 47 (0.04%)
30–39 166 953 19.69% 114 0.07% 144 268 117 (0.08%) 23 (0.02%) 30 (0.02%) 170 (0.12%)
40–49 152 374 17.97% 359 0.24% 135 390 386 (0.29%) 63 (0.05%) 63 (0.05%) 512 (0.38%)
50–59 140 668 16.59% 1291 0.92% 127 233 1222 (0.96%) 217 (0.17%) 151 (0.12%) 1590 (1.25%)
60–69 116 604 13.75% 4463 3.83% 107 376 3877 (3.61%) 726 (0.68%) 293 (0.27%) 4896 (4.56%)
70–79 71 472 8.43% 10 548 14.76% 67 061 7475 (11.15%) 2235 (3.33%) 658 (0.98%) 10 368 (15.46%)
80–89 39 084 4.61% 12 785 32.71% 36 372 7082 (19.47%) 3706 (10.19%) 1071 (2.94%) 11 859 (32.60%)
90+ 10 542 1.24% 4351 41.27% 9377 1804 (19.24%) 1344 (14.33%) 494 (5.27%) 3642 (38.84%)
Total 848 031 100% 33 945 4.00% 754 115 21 990 (2.92%) 8323 (1.10%) 2771 (0.37%) 33 084 (4.39%)
Males
20–29 93 259 14.71% 42 0.05% 76 025 46 (0.06%) 13 (0.02%) 14 (0.02%) 73 (0.10%)
30–39 114 061 17.99% 117 0.10% 95 280 78 (0.08%) 31 (0.03%) 43 (0.05%) 152 (0.16%)
40–49 116 040 18.30% 370 0.32% 100 486 338 (0.34%) 64 (0.06%) 100 (0.10%) 502 (0.50%)
50–59 113 395 17.88% 1274 1.12% 101 292 1232 (1.22%) 248 (0.24%) 180 (0.18%) 1660 (1.64%)
60–69 101 602 16.02% 4575 4.50% 93 247 3926 (4.21%) 880 (0.94%) 350 (0.38%) 5156 (5.53%)
70–79 62 713 9.89% 9551 15.23% 58 606 6889 (11.75%) 2084 (3.56%) 712 (1.21%) 9685 (16.53%)
80–89 28 110 4.43% 9136 32.50% 26 129 5275 (20.19%) 2586 (9.90%) 892 (3.41%) 8753 (33.50%)
90+ 4844 0.76% 2087 43.08% 4331 892 (20.60%) 712 (16.44%) 277 (6.40%) 1881 (43.43%)
Total 634 024 100% 27 152 4.28% 555 396 18 676 (3.36%) 6618 (1.19%) 2568 (0.46%) 27 862 (5.02%)
†Number of patients meeting Australian Health Study criteria. Percentage of patients with a General Practitioner encounter or pathology result in 2016. ACR,
albumin/creatinine ratios; CKD, chronic kidney disease; eGFR, estimated glomerular ﬁltration rate.
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but, appropriately, patients with a diagnosis of CKD had an
eGFR at an annual rate of 87.3%, those with diabetes
67.7%, with CVD 58.8%, HT 58.4%, and AF 57.5%. Those
with anxiety disorder, as an example of a disorder not noted
as a CKD comorbidity, were only a little above the 40–45%
rate at 49.6%. This suggests GP and their patients were
aware of a need to check renal function in the face of
known CKD or comorbidities of highest risk for the develop-
ment, or progression of CKD.
The comorbidities of CKD patients managed by GP may
be concordant conditions overlapping in pathophysiology
and treatment goals such as HT and diabetes, or discordant
with opposing management plans that may exacerbate
CKD, such as arthritis and the use of non-steroidal anti-
inﬂammatory drugs.25 Further exploration of this dataset to
investigate the use of medications in the management of
concordant and non-concordant conditions is planned.
The NPS MedicineWise MedicineInsight dataset also has
inherent limitations relating to its reliance on complete and
accurate recording of data by GP, and the use of ‘condition
ﬂags’. These limitations were partly illustrated by the ﬁnding
that less than 25% of the patient with potentially diagnos-
able CKD had CKD documented as a ‘condition ﬂag’ in their
EHR. Comorbidities were recorded based on ‘condition ﬂags’
provided by MedicineInsight, using an algorithm that ana-
lyses coded and free-text patient information; this algorithm
has not been validated. Other limitations were the absence
of ‘condition ﬂags’ for haematuria, previous acute kidney
injury, glomerulonephritis, or current renal replacement
therapy, all factors of interest in describing the Australian
population’s CKD epidemiology.
Despite its limitations, the NPS MedicineWise MedicineIn-
sight dataset could meet the call by researchers for the use
of aggregated EHR data to evaluate primary care
interventions,26 while contributing to data-linkage studies
that inform community-based needs assessment27 and to
drug post-marketing sentinel systems.28 In the area of
Australian patients with CKD, it is likely to provide a more
MedicineInsight Dataset 
Patients = 1,483,416 
Patients identified as having at least one 
eGFR and/or ACR measurement  
Patients = 958,986 
Patients identified as not having an eGFR 
or an ACR measurement  
Patients = 524,430 
Patients identified as having an eGFR 
measurement less than 60 
mL/min/1.73m2 and/or an abnormal ACR 
result 
Patients = 113,517 
Patients identified as not meeting 
definition of CKD 
Patients = 52,415 
Patients identified as having at least two 
eGFR results less than 60 mL/min/1.73m2 
and/or two abnormal ACR results at least 
90 days apart 
Patients = 61,102 
Patients identified as not having an eGFR 
measurement less than 60 
mL/min/1.73m2, or an abnormal ACR 
result 
Patients = 893,682 
Fig. 1 Flow Chart of patient inclusions
and exclusions.
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valid source of information for pre-dialysis patients than
current registries.24 The relatively large group of patients
comprising those with CKD stages 1–3 disease, as is compat-
ible with guideline care, are managed by their general prac-
tice team.16 It is likely the analysis of this dataset will assist
the specialty of general practice to optimize the prevention
of CKD and care of patients with CKD.
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Fig. 2 Venn diagram of chronic kidney disease and key comorbidities.
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